Financial Instruments and Fair Value Measurements (Narrative) (Details) CAD in Millions, $ in Millions	12 Months Ended
	Sep. 30, 2016 USD ($)	Sep. 30, 2016 CAD	Sep. 25, 2015 CAD	Aug. 31, 2016 USD ($)	Feb. 01, 2016 USD ($)	Sep. 25, 2015 USD ($)	Sep. 25, 2015 CAD	Aug. 31, 2014 USD ($)	Aug. 14, 2014 USD ($)	Apr. 30, 2013	Oct. 01, 2012 USD ($)
Novartis 2015 and 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Annual Payments	$ 25.0
Novartis, Subsequent to 2016 till FDA Approval
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Annual Payments	25.0
Novartis, Subsequent to FDA Approval
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Potential Payment	$ 25.0
CNS Therapeutics, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration upon acquisition											$ 6.9
Maximum contingent payments for acquisition											$ 9.0
Discount rate	1.00%	1.00%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability	$ 0.9
Questcor Pharmaceuticals, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration upon acquisition									$ 0.0
Maximum contingent payments for acquisition	$ 165.0
Discount rate	4.70%	4.70%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability	$ 123.4							$ 195.4
Hemostasis Products
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration upon acquisition					$ 52.0
Maximum contingent payments for acquisition					395.0
Stratatech [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration upon acquisition				$ 54.9
Maximum contingent payments for acquisition				$ 121.0
4.00% term loan due February 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate	4.00%	4.00%
Debentures | 8.00% debentures due March 2023 | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	8.00%
Debentures | 9.50% debentures due May 2022 | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	9.50%
Senior Notes | 3.50% notes due April 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate										3.50%
Senior Notes | 3.50% notes due April 2018 | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	3.50%
Senior Notes | 4.75% notes due April 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate										4.75%
Senior Notes | 4.75% notes due April 2023 | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	4.75%
Senior Notes | 5.75% notes due August 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate	5.75%	5.75%
Stated interest rate								5.75%
Debentures | Four Point Eight Eight Percent Notes [Member] | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	4.875%
Debentures | Five Point Five Percent Notes [Member] | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	5.50%
Debentures | 5.625% notes due October 2023 | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stated interest rate	5.625%
Carrying Value | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash	$ 19.1					$ 66.3
Carrying Value | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash surrender value of life insurance	67.6					66.8
BioVectra Inc [Member] | Questcor Pharmaceuticals, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration upon acquisition | CAD							CAD 50.0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements | CAD		CAD 40.0	CAD 5.0
PreveLeak [Member] | Hemostasis Products
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability					10.6
Raplixa [Member] | Hemostasis Products
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration upon acquisition					$ 52.0
Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration upon acquisition	247.8					174.6
Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration upon acquisition	0.0					0.0
Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration upon acquisition	0.0					0.0
Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration upon acquisition	247.8					$ 174.6
Recurring | Level 3 | Stratatech [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability	54.9
Recurring | PreveLeak [Member] | Level 3 | Hemostasis Products
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability	11.0
Recurring | Raplixa [Member] | Level 3 | Hemostasis Products
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration upon acquisition	$ 57.7